Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

doi:10.3748/wjg.v23.i36.6549

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (36172)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

3170

WORD

397

HTML

27850

Tables (1-2)

140

Sum=31557

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

697

Download

741

Sum=1438

Publishing Process of This Article

Item

Count

Browse

1377

Download

1800

Sum=3177

Sep 28, 2017 (publication date) through May 11, 2024

Times Cited of This Article

Times Cited (166)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 28, 2017; 23(36): 6549-6570
Published online Sep 28, 2017. doi: 10.3748/wjg.v23.i36.6549

Table 2 Treatment options for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Lifestyle changes	Weight loss
	Dietary changes
	Exercise
Insulin sensitizers	Thiazolidinedione’s
Insulin sensitizers	Metformin
Lipid lowering agents	Statins
Lipid lowering agents	Ezetimibe
Hepatoprotective agents	UDCA
Antioxidants	Vitamin E
Incretin analogues	GLP-1 agonists
Incretin analogues	DPP-IV inhibitors
Anti-inflammatory agents	PTX
Others	Probiotics
	Angiotensin receptor blockers
	Endocannabinoid antagonists
	Bariatric surgery
	Liver transplantation
Potential new therapeutic options	Caspases inhibitors
	ASK1 inhibitors
	p38 MAPK inhibitors
	PPAR- alpha and delta agonists
	FXR agonists
	NOX-1/4 inhibitors
	Galectin-3 antagonists
	Acetyl CoA carboxylase inhibitors
	FGF-21 and FGF-19 analogues
	CCR2 and CCR5 inhibitors
	SCD-1 inhibitors
	Lysyl oxidase-like 2 inhibitors
	Sirtuins

GLP-1: Glucagon-like peptide 1; DPP-IV: Dipeptidyl-peptidase IV; PTX: Pentoxifylline; PPAR: Peroxisome proliferator activated receptor; NOX: NADPH oxidase; FGF-21: Fibroblast growth factor 21; SCD1: Stearoyl coenzyme A desaturase 1.

Citation: Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570
URL: https://www.wjgnet.com/1007-9327/full/v23/i36/6549.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i36.6549